ISSN 1004-4140
CN 11-3017/P
| Citation: |
RONG P, LI M, YANG S W, et al. MRI Study on the Effects of Platinum-based Chemotherapy on Brain Lateralization in Patients with Lung Cancer[J]. CT Theory and Applications, 2025, 34(3): 447-454. DOI: 10.15953/j.ctta.2025.025. (in Chinese).
|
This study aimed to investigate the impact of platinum-based chemotherapy on cerebral cortex thickness in patients with lung cancer, focusing on bilateral hemispheres and lateralization characteristics. Data from 191 participants who underwent head magnetic resonance imaging (MRI) with a 3D-T1WI sequence at Nanjing Drum Tower Hospital between January 2019 and June 2021 were retrospectively analyzed. The sample included 38 patients with lung cancer who were treated with platinum-based chemotherapy, 113 patients with lung cancer who did not receive any form of chemotherapy, and 40 healthy controls matched for age, sex, and educational level. Cortical thickness changes were compared among the three groups using a two-sample t-test to evaluate specific differences. Significant differences in the thicknesses of multiple cortical regions were observed between patients with lung cancer (both those who received and did not receive platinum-based chemotherapy) and healthy controls. Notably, patients with lung cancer who did not receive chemotherapy exhibited more pronounced differences in the anterior cingulate gyrus and superior temporal cortex in both hemispheres than the healthy control and chemotherapy groups. Additionally, in the healthy control group and patients with lung cancer receiving platinum-based chemotherapy, the thickness of the right inferior frontal gyrus decreased with age; however, this correlation was not observed in patients with lung cancer who did not receive chemotherapy. This study suggests that lung cancer may lead to cortical atrophy, particularly in patients who have not received platinum-based anticancer drugs. Furthermore, structural changes in the brain induced by disease exhibited a certain degree of lateralization.
| [1] |
BARTA J A, POWELL C A, WISNIVESKY J P. Global epidemiology of lung cancer[J]. Ann Glob Health, 2019, 85. DOI: 10.5334/aogh.2419.
|
| [2] |
XIA C, DONG X, LI H, et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants[J]. Chinese Medical Journal, 2022, 135: 584-590. DOI: 10.1097/cm9.0000000000002108.
|
| [3] |
ROSSI A, Di MAIO M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles[J]. Expert Review of Anticancer Therapy, 2016, 16: 653-660. DOI: 10.1586/14737140.2016.1170596.
|
| [4] |
NAGASAKA M, GADGEEL S M. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer[J]. Expert Review of Anticancer Therapy, 2018, 18: 63-70. DOI: 10.1080/14737140.2018.1409624.
|
| [5] |
ARBOUR K C, RIELY G J. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review[J]. The Journal of the American Medical Association, 2019, 322: 764-774. DOI: 10.1001/jama.2019.11058.
|
| [6] |
RAJESWARAN A, TROJAN A, BURNAND B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials[J]. Lung Cancer, 2008, 59: 1-11. DOI: 10.1016/j.lungcan.2007.07.012.
|
| [7] |
MCWHINNEY S R, GOLDBERG R M, MCLEOD H L. Platinum neurotoxicity pharmacogenetics[J]. Molecular Cancer Therapeutics, 2009, 8: 10-16. DOI: 10.1158/1535-7163.mct-08-0840.
|
| [8] |
SIMó M, VAQUERO L, RIPOLLéS P, et al. Brain damage following prophylactic cranial irradiation in lung cancer survivors[J]. Brain Imaging and Behavior, 2016, 10: 283-295. DOI: 10.1007/s11682-015-9393-5.
|
| [9] |
吴川, 陈功, 董立, 等. 非小细胞肺癌患者大脑皮层变化及临床相关因素的初步研究[J]. 肿瘤预防与治疗, 2021, 34: 1026-1034. DOI: 10.3969/j.issn.1674-0904.2021.11.006.
WU C, CHEN G, DONG L, et al. A preliminary study of cerebral cortex changes in NSCLC patients and its related clinical factors[J]. Journal of Cancer Control and Treatment, 2021, 34: 1026-1034. DOI: 10.3969/j.issn.1674-0904.2021.11.006. (in Chinese).
|
| [10] |
AMIDI A, WU L M. Structural brain alterations following adult non-CNS cancers: A systematic review of the neuroimaging literature[J]. Acta Oncologica, 2019, 58: 522-536. DOI: 10.1080/0284186x.2018.1563716.
|
| [11] |
ROE J M, VIDAL-PIñEIRO D, SøRENSEN ø, et al. Asymmetric thinning of the cerebral cortex across the adult lifespan is accelerated in Alzheimer's disease[J]. Nature Communications, 2021, 12: 721. DOI: 10.1038/s41467-021-21057-y.
|
| [12] |
HUTSLER J, GALUSKE R A. Hemispheric asymmetries in cerebral cortical networks[J]. Trends in Neurosciences, 2003, 26: 429-435. DOI: 10.1016/s0166-2236(03)00198-x.
|
| [13] |
CARNE R P, VOGRIN S, LITEWKA L, et al. Cerebral cortex: An MRI-based study of volume and variance with age and sex[J]. Journal of Clinical Neuroscience, 2006, 13: 60-72. DOI: 10.1016/j.jocn.2005.02.013.
|
| [14] |
CORREA D D, ROOT J C, KRYZA-LACOMBE M, et al. Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: A pilot study[J]. Brain Imaging and Behavior, 2017, 11: 1652-1663. DOI: 10.1007/s11682-016-9608-4.
|
| [15] |
SEKERES M J, BARDLEY-GARCIA M, MARTINES-CANABAL A, et al. Chemotherapy-induced cognitive impairment and hippocampal neurogenesis: A review of physiological mechanisms and interventions[J]. International Journal of Molecular Sciences, 2021, 22. DOI: 10.3390/ijms222312697.
|
| [16] |
WRIGHT K, DIGBY G C, GYAWALI B, et al. Malignant superior vena cava syndrome: A scoping review[J]. Journal of Thoracic Oncology, 2023, 18: 1268-1276. DOI: 10.1016/j.jtho.2023.04.019.
|
| [17] |
AKYUZ E, PALAT A K, EROGLU E, et al. Revisiting the role of neurotransmitters in epilepsy: An updated review[J]. Life Sciences, 2021, 265: 118826. DOI: 10.1016/j.lfs.2020.118826.
|
| [18] |
QUAIL D F, JOYCE J A. Microenvironmental regulation of tumor progression and metastasis[J]. Nature Medicine, 2013, 19: 1423-1437. DOI: 10.1038/nm.3394.
|
| [19] |
GüNTüRKüN O, STRöCKENS F, OCKLENBURG S. Brain lateralization: A comparative perspective[J]. Physiological Reviews, 2020, 100: 1019-1063. DOI: 10.1152/physrev.00006.2019.
|
| [20] |
BERCIK P, COLLINS S M. The effects of inflammation, infection and antibiotics on the microbiota-gut-brain axis[J]. Advances in Experimental Medicine and Biology, 2014, 817: 279-289. DOI: 10.1007/978-1-4939-0897-4_13.
|
| [21] |
AVISAR A, RIVER Y, SCHIFF E, et al. Chemotherapy-related cognitive impairment: Does integrating complementary medicine have something to add? Review of the literature[J]. Breast Cancer Research and Treatment, 2012, 136: 1-7. DOI: 10.1007/s10549-012-2211-5.
|
| [22] |
PARK H Y, LEE H, SOHN J, et al. Increased resting-state cerebellar-cortical connectivity in breast cancer survivors with cognitive complaints after chemotherapy[J]. Scientific Reports, 2021, 11: 12105. DOI: 10.1038/s41598-021-91447-1.
|
| [23] |
ROOT J C, PERGOLIZZI D, PAN H, et al. Prospective evaluation of functional brain activity and oxidative damage in breast cancer: Changes in task-induced deactivation during a working memory task[J]. Brain Imaging and Behavior, 2021, 15: 1364-1373. DOI: 10.1007/s11682-020-00335-1.
|
| [24] |
周燕飞, 李竞, 伏晓, 等. 乳腺癌患者化疗早期大脑皮层表面形态学改变和癌症相关疲劳变化的关系: 基于表面形态测量方法[J]. 磁共振成像, 2024, 15: 48-55. DOI: 10.12015/issn.1674-8034.2024.02.007.
ZHOU Y F, LI J, FU X, et al. Surface-based morphological study on the relationship between cortical surface morphological changes and cancer-related fatigue changes in early chemotherapy for breast cancer[J]. Chinese Journal of Magnetic Resonance Imaging, 2024, 15: 48-55. DOI: 10.12015/issn.1674-8034.2024.02.007.(in Chinese).
|
| [25] |
DEKEN J F, LöSCHER W. The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses[J]. Clinical Cancer Research, 2007, 13: 1663-1674. DOI: 10.1158/1078-0432.ccr-06-2854.
|
| [26] |
WARDILL H R, MANDER K A, VAN SEBILLE Y Z, et al. Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction[J]. International Journal of Cancer, 2016, 139: 2635-2645. 10.1002/ijc. 30252.
|
| [27] |
PARK S B, KRISHNAN A V, LIN C S, et al. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies[J]. Current Medicinal Chemistry, 2008, 15: 3081-3094. DOI: 10.2174/092986708786848569.
|
| [28] |
MCDONALD B C, CONROY S K, AHLES T A, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: A prospective MRI study[J]. Breast Cancer Research and Treatment, 2010, 123: 819-828. DOI: 10.1007/s10549-010-1088-4.
|
| [29] |
MCDONALD B C, CONROY S K, SMITH D J, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: A replication and extension study[J]. Brain Behavior and Immunity, 2013, 30(S): S117-125. DOI: 10.1016/j.bbi.2012.05.007.
|
| [30] |
VARDY J L, DHILLON H M, POND G R, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: A prospective, longitudinal, controlled study[J]. Journal of Clinical Oncology, 2015, 33: 4085-4092. DOI: 10.1200/jco.2015.63.0905.
|
| [31] |
AHLES T A, ROOT J C. Cognitive effects of cancer and cancer treatments[J]. Annual Review of Clinical Psychology, 2018, 14: 425-451. DOI: 10.1146/annurev-clinpsy-050817-084903.
|
| [32] |
MANDELBLLATT J S, SMALL B J, LUTA G, et al. Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study[J]. Journal of Clinical Oncology, 2018, 36: Jco1800140. DOI: 10.1200/jco.18.00140.
|
| [33] |
NGUYEN L D, EHRLICH B E. Cellular mechanisms and treatments for chemobrain: Insight from aging and neurodegenerative diseases[J]. EMBO Molecular Medicine, 2020, 12: e12075. DOI: 10.15252/emmm.202012075.
|
| [34] |
TREJO M J, BELL M L, DHILLON H M, et al. Baseline quality of life is associated with survival among people with advanced lung cancer[J]. Journal of Psychosocial Oncology, 2020, 38: 635-641. DOI: 10.1080/07347332.2020.1765065.
|
| [35] |
OXMAN T E, SILBERFARB P M. Serial cognitive testing in cancer patients receiving chemotherapy[J]. American Journal of Psychiatry, 1980, 137: 1263-1265. DOI: 10.1176/ajp.137.10.1263.
|
| [36] |
RAO V, BHUSHAN R, KUMARI P, et al. Chemobrain: A review on mechanistic insight, targets and treatments[J]. Advances in Cancer Research, 2022, 155: 29-76. DOI: 10.1016/bs.acr.2022.04.001.
|
| [37] |
SIMó M, ROOT J C, VAQUERO L, et al. Cognitive and brain structural changes in a lung cancer population[J]. Journal of Thoracic Oncology, 2015, 10: 38-45. DOI: 10.1097/jto.0000000000000345.
|
| [38] |
KOPPELMANS V, de GROOT M, de RUITER M B, et al. Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy[J]. Human Brain Mapping, 2014, 35: 889-899. DOI: 10.1002/hbm.22221.
|
| [39] |
STOUTEN-KEMPERMAN M M, de RUITER M B, KOPPELMANS V, et al. Neurotoxicity in breast cancer survivors ≥10 years post-treatment is dependent on treatment type[J]. Brain Imaging and Behavior, 2015, 9: 275-284. DOI: 10.1007/s11682-014-9305-0.
|
| [40] |
LIU S, NI J, YAN F, et al. Functional changes of the prefrontal cortex, insula, caudate and associated cognitive impairment (chemobrain) in NSCLC patients receiving different chemotherapy regimen[J]. Frontiers in Oncology, 2022, 12: 1027515. DOI: 10.3389/fonc.2022.1027515.
|
Supported by: Beijing Renhe Information Technology Co. Ltd 
DownLoad: